Title:
PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA
Document Type and Number:
WIPO Patent Application WO/2024/047811
Kind Code:
A1
Abstract:
Provided is a method for treating lymphoma. Use is made of a composition for treating lymphoma, the composition containing BCV, a pharmaceutically acceptable salt thereof, or a solvate of the BCV or the salt thereof. The lymphoma may be MYC-positive lymphoma. The lymphoma may be EBV-positive lymphoma. The pharmaceutical composition may be used together with a chemotherapeutic agent.
Inventors:
CHAN JASON (SG)
ONG CHOON KIAT (SG)
HAZAMA MASATOSHI (JP)
FUKUSHIMA KOJI (JP)
ONG CHOON KIAT (SG)
HAZAMA MASATOSHI (JP)
FUKUSHIMA KOJI (JP)
Application Number:
PCT/JP2022/032837
Publication Date:
March 07, 2024
Filing Date:
August 31, 2022
Export Citation:
Assignee:
SYMBIO PHARMACEUTICALS LTD (JP)
International Classes:
A61K31/675; A61K45/00; A61P35/00; A61P43/00
Foreign References:
| JP2013501056A | 2013-01-10 |
Other References:
TIPPIN TIMOTHY K., MORRISON MARION E., BRUNDAGE THOMAS M., MOMMÉJA-MARIN HERVÉ: "Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies", THERAPEUTIC DRUG MONITORING., LIPPINCOTT WILLIAMS AND WILKINS., NEW YORK, NY, US, vol. 38, no. 6, 1 December 2016 (2016-12-01), NEW YORK, NY, US , pages 777 - 786, XP093143712, ISSN: 0163-4356, DOI: 10.1097/FTD.0000000000000353
ABDULKARIM B, ET AL: "Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 22, no. 15, 17 April 2003 (2003-04-17), London , pages 2260 - 2271, XP002311595, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1206402
LUPPI M; TROVATO R; BAROZZI P; VALLISA D; ROSSI G; RE A; RAVAZZINI L; POTENZA L; RIVA G; MORSELLI M; LONGO G; CAVANNA L; RONCAGLIA: "Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 19, no. 3, 20 January 2005 (2005-01-20), London, pages 473 - 476, XP037781058, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2403646
RUOZI, B. ; RIVA, G. ; BELLETTI, D. ; TOSI, G. ; FORNI, F. ; MUCCI, A. ; BAROZZI, P. ; LUPPI, M. ; VANDELLI, M.A.: "Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 41, no. 2, 9 October 2010 (2010-10-09), NL , pages 254 - 264, XP027226317, ISSN: 0928-0987
ABDULKARIM B, ET AL: "Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 22, no. 15, 17 April 2003 (2003-04-17), London , pages 2260 - 2271, XP002311595, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1206402
LUPPI M; TROVATO R; BAROZZI P; VALLISA D; ROSSI G; RE A; RAVAZZINI L; POTENZA L; RIVA G; MORSELLI M; LONGO G; CAVANNA L; RONCAGLIA: "Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 19, no. 3, 20 January 2005 (2005-01-20), London, pages 473 - 476, XP037781058, ISSN: 0887-6924, DOI: 10.1038/sj.leu.2403646
RUOZI, B. ; RIVA, G. ; BELLETTI, D. ; TOSI, G. ; FORNI, F. ; MUCCI, A. ; BAROZZI, P. ; LUPPI, M. ; VANDELLI, M.A.: "Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 41, no. 2, 9 October 2010 (2010-10-09), NL , pages 254 - 264, XP027226317, ISSN: 0928-0987
Attorney, Agent or Firm:
SK INTELLECTUAL PROPERTY LAW FIRM et al. (JP)
Download PDF:
Previous Patent: ELECTRONIC CONTROL DEVICE
Next Patent: INFORMATION PROCESSING DEVICE, OUTPUT METHOD, AND OUTPUT PROGRAM
Next Patent: INFORMATION PROCESSING DEVICE, OUTPUT METHOD, AND OUTPUT PROGRAM